Baoshan Cao

机构：Peking University, Sidney Kimmel Cancer Center, Peking University Third Hospital · ORCID：0000-0001-7939-4820

发表论文 100 篇 · 总被引 844 次 · h-index 15

代表论文

• Targeting KRAS: from metabolic regulation to cancer treatment (2025 · Molecular Cancer · 被引 58)
• Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial (2025 · The Lancet Respiratory Medicine · 被引 10)
• Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer. (2025 · Journal of Clinical Oncology · 被引 9)
• Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites (2025 · Gut · 被引 8)
• Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study (2025 · European Journal of Cancer · 被引 3)
• Liver protection of CACA technical guidelines for holistic integrative management of cancer (2025 · Holistic Integrative Oncology · 被引 3)